SCYNEXIS (NASDAQ:SCYX – Get Free Report) and Metagenomi (NASDAQ:MGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Volatility & Risk
SCYNEXIS has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
Earnings & Valuation
This table compares SCYNEXIS and Metagenomi”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SCYNEXIS | $3.75 million | 8.94 | -$21.29 million | ($0.40) | -2.00 |
| Metagenomi | $52.29 million | 1.90 | -$78.06 million | ($2.36) | -1.12 |
SCYNEXIS has higher earnings, but lower revenue than Metagenomi. SCYNEXIS is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for SCYNEXIS and Metagenomi, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SCYNEXIS | 1 | 0 | 0 | 0 | 1.00 |
| Metagenomi | 1 | 0 | 3 | 0 | 2.50 |
Metagenomi has a consensus target price of $10.00, suggesting a potential upside of 277.36%. Given Metagenomi’s stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than SCYNEXIS.
Institutional & Insider Ownership
54.4% of SCYNEXIS shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Comparatively, 17.8% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares SCYNEXIS and Metagenomi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SCYNEXIS | -599.05% | -43.04% | -28.21% |
| Metagenomi | -257.99% | -37.84% | -27.15% |
Summary
Metagenomi beats SCYNEXIS on 9 of the 14 factors compared between the two stocks.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
